Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rintatolimod,Celecoxib,Interferon Alfa-2B
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Roswell Park Comprehensive Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Primary endpoint of the study was met for Ampligen (rintatolimod), selective TLR3 ligand, evidenced by increased CD8a expression post-treatment (p=0.046), as a component of treatment for colorectal cancer metastatic to the liver.
Product Name : Ampligen
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : Rintatolimod,Celecoxib,Interferon Alfa-2B
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Roswell Park Comprehensive Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable